Roy Fleischmann puts the new FDA boxed warning of increased pulmonary embolism and death risk with tofacitinib into context for rheumatologists and their patients.
48-week results from the SELECT-COMPARE study indicate that upadacitinib has sustained efficacy in patients with rheumatoid arthritis, and that individuals with an inadequate response to upadacitinib or adalimumab may benefit from switching to the alternate therapy.
Antigone Pieta, Dionysis Nikolopoulos, and Antonis Fanouriakis discuss the causes and management of neuropsychiatric systemic lupus erythematosus, and outline unmet needs in the diagnosis and treatment of this disease.
Neutrophil-derived biomarkers correlate with disease activity and can predict joint space narrowing and erosive disease among patients with rheumatoid arthritis, researchers report.
EULAR has developed up-to-date guidelines for the use of vaccinations in patients with rheumatic diseases, based on a systematic literature review and expert opinion.
Roy Fleischmann puts the new FDA boxed warning of increased pulmonary embolism and death risk with tofacitinib into context for rheumatologists and their patients.
One study has demonstrated an elevated risk for serious infection among rheumatoid arthritis patients treated with tumor necrosis factor inhibitors versus conventional Disease‐Modifying Antirheumatic Drugs, whereas another has found no increased risk.
medwireNews takes a look at the efficacy and safety profiles of JAK inhibitors for the treatment of rheumatoid arthritis, and addresses some common questions about their use.
Rheumatoid arthritis patients treated with the JAK1 selective inhibitor upadacitinib experience greater improvement in the signs and symptoms of disease than those given placebo or adalimumab, indicate findings from the SELECT-COMPARE trial.
